The trial will be a randomized, double-blind placebo-controlled study where patients will be assigned one of three options: hydroxychloroquine, a combination of hydroxychloroquine and the antibiotic azithromycin or a placebo.
The trial will be conducted at more than a dozen sites in the U.S. and begin in the next few weeks, the drugmaker said.
Hydroxychloroquine is the decades-old malaria drug that the president has urged COVID-19 patients to try. It has been regularly given to COVID-19 patients, though it hasn’t been proven to be effective in treating the disease.
Read the full news release here.
More articles on pharmacy:
CVS, UCLA Health unite to free hospital beds for COVID-19 patients
NIH teams up with 16 drugmakers to speed COVID-19 vaccine development
16 recent drug, device recalls
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
